Novel treatment for cardiovascular disease

Purpose and goal

The long-term aim is to develop a drug addressing the cardiovascular residual risk in patients with atherogenic dyslipidemia. For this project our aim was to prepare the project for the commercialization process by performing proof-of-principle studies and developing strategies for this process, ultimately securing future funding of the project. Through the support from Vinnova we have entered a collaboration fulfilling this goal.

Expected results and effects

group, through Lipigon Pharmaceuticals, adds expert knowledge of the target and AstraZeneca contributes with drug development capabilities. Through this we expect Lipigon to be able to expend and initiate new projects. Thus this Vinnova project has contributed positively to national growth.

Planned approach and implementation

The project has focused on business development and technical verification with future investments and/or collaborations in mind. All of the specific aims have not been fulfilled but the work processes have all contributed to goal achievement. By allowing flexibility in the project and being perceptive to the project management Vinnova has played an important role in the success of the project.